Clinical Trials
7
3 active
Approvals
2
Total approvals
Agencies
1
Regulatory bodies
Founded
1876
Completed
2
28.6%
Not yet recruiting
3
42.9%
Recruiting
2
28.6%
- Immunocine Cancer Center has appointed Stephen J. Noga, M.D., Ph.D., a former Johns Hopkins faculty member with over three decades of oncology experience, as its new Chief Medical Officer. - Dr. Noga's early doctoral research contributed to the identification of dendritic cells, which are now central to Immunocine's personalized cancer immunotherapy platform. - In his new role, Dr. Noga will oversee medical operations and guide development of therapies that use a patient's own tumor tissue and dendritic cells to train the immune system against their cancer. - Dr. Noga previously held senior leadership roles at Takeda Oncology, Exact Sciences, and the University of Maryland Greenbaum Comprehensive Cancer Center.
- The NEXIS trial found that combining daily in-bed cycling with intravenous amino acid supplementation did not significantly improve 6-minute walk distance at hospital discharge compared to usual care alone in ICU patients with acute respiratory failure. - At discharge, median 6MWD was 108 meters in the intervention group versus 95 meters in the control group, with no significant differences in quadriceps force, grip strength, or other physical function measures. - Researchers recommend against higher protein intake during the acute phase of critical illness, consistent with three prior large randomized trials showing no benefit and potential harm. - Early mobilization remains safe and beneficial for ICU patients, but the additive strategy of protein supplementation does not enhance outcomes, likely due to anabolic resistance in critically ill patients.
- The 20th annual Global Wellness Summit will convene in Phuket, Thailand, from November 10–13, 2026, under the theme "The Science, Art and Soul of Wellness." - Leading geroscientist Andrea Maier, MD, PhD, will discuss the future of precision geromedicine and radically personalized longevity science, while Blue Zones founder Dan Buettner will keynote on lifestyle-driven healthspan. - The Global Wellness Institute will unveil the 2026 Global Wellness Economy Monitor, providing new data on the $6.8 trillion global wellness economy and the rapidly expanding Asian wellness market. - A first-of-its-kind Intentional Spaces Design Challenge, developed with Johns Hopkins University's Center for Applied Neuroaesthetics, will explore how neuroarchitecture can shape healthier buildings and communities.
- Johns Hopkins researchers developed patient-derived hindbrain organoids that capture key molecular features of Alzheimer's disease and reveal individual variation in drug response. - When exposed to the SSRI escitalopram oxalate, some organoids showed strong molecular responses while others showed little change, mirroring real-world clinical variability. - Extracellular vesicles released by organoids contained Alzheimer's-linked proteins including RAB3A, NSF, and ATCAY at lower levels, suggesting potential as non-invasive biomarkers. - The study, published in Alzheimer's & Dementia, may eventually enable liquid biopsy-based patient stratification and personalized treatment selection for neuropsychiatric symptoms.
- Charles River Laboratories signed agreements to acquire K.F. (Cambodia) Ltd. for approximately $510 million to strengthen its non-human primate supply chain, with the transaction expected to be accretive to non-GAAP earnings per share by $0.25 in 2026 and $0.60 in 2027. - The company exercised its option to acquire the remaining 79% stake in PathoQuest SAS for approximately $60 million to enhance its next-generation sequencing capabilities for biopharmaceutical manufacturing quality-control testing. - Former FDA Deputy Principal Commissioner Dr. Namandjé Bumpus was appointed as Senior Vice President, Chief Scientific and Innovation Officer to lead the company's scientific strategy and advance new approach methodologies. - Charles River reported improved Discovery and Safety Assessment demand trends in the second half of 2025, with a fourth-quarter net book-to-bill of approximately 1.1x, and expects at least flat organic revenue growth for 2026.
- Nature Cell has revived development of Vascostem, an autologous adipose-derived stem cell therapy for Critical Limb Ischemia, targeting FDA approval by 2030 through RMAT designation. - Clinical trials demonstrated complete prevention of major amputation in 15 patients at 6-month follow-up, with only 33.3% requiring minor amputation procedures. - The company has secured advisory support from 2019 Nobel Prize winner Professor Gregg Semenza to optimize treatment approaches and strengthen regulatory strategy. - Vascostem CLI will be manufactured at a Baltimore GMP facility with an anticipated treatment price exceeding $50,000 upon U.S. commercialization.
- Korean biotechnology company Nature Cell is establishing a 100,000 square-foot stem cell manufacturing facility in Baltimore, bringing an estimated 500 new full-time jobs to the region by 2031. - The facility will focus on knee osteoarthritis and Alzheimer's stem cell research, clinical trials, and manufacturing investigational products, with plans to produce one million doses annually of JointStem, an intra-articular stem cell injection. - Maryland is providing $4 million in conditional loans through the Department of Commerce, while Baltimore Development Corporation is contributing $400,000 to support the project and expedite regulatory approvals. - Nature Cell cited Maryland's Stem Cell Research Fund, highly-skilled technical workforce, and collaborative academic network anchored by Johns Hopkins University as key factors in choosing the state for its U.S. operations.
- A phase 1 study of 32 pediatric patients aged 7-17 years demonstrated that Anaphylm sublingual epinephrine film achieved pharmacokinetic and pharmacodynamic profiles comparable to those previously observed in adults. - The sublingual film produced a maximum epinephrine concentration of 568.6 pg/mL in children compared to 470.2 pg/mL in adults, with faster time to peak concentration (10 minutes vs 12 minutes). - Treatment-emergent adverse events occurred in 84.4% of pediatric participants but were predominantly mild and self-resolving, with safety profiles consistent with adult populations. - The needle-free delivery system offers a potential alternative to traditional epinephrine auto-injectors for managing anaphylaxis in children weighing at least 30 kg.
- Two clinical trials demonstrate that vatiquinone and omaveloxolone provide durable benefits in slowing disease progression for patients with Friedreich's ataxia over extended treatment periods. - Vatiquinone showed a 4.809-point improvement in mFARS scores compared to natural history controls over 24 months, with statistical significance (P<0.0001). - Omaveloxolone demonstrated sustained efficacy over 4 years in the longest study of a disease-modifying therapy for Friedreich's ataxia patients. - Both treatments were well-tolerated with no treatment-related serious adverse events, marking significant progress in rare neurodegenerative disease management.
- A modified DASH diet tailored for diabetes (DASH4D) significantly reduced systolic blood pressure by 4.6 mm Hg and diastolic pressure by 2.3 mm Hg in type 2 diabetes patients. - The blood pressure reduction was achieved even in patients already taking multiple antihypertensive medications, with 66% of participants on two or more blood pressure drugs. - The DASH4D diet combines traditional DASH principles with diabetes-specific modifications including lower carbohydrates, higher unsaturated fats, and reduced potassium intake. - Sodium reduction appeared to have a stronger impact on lowering blood pressure than the DASH4D diet alone, highlighting the importance of dietary sodium restriction in diabetes management.
